Reduction in postprandial TG concentrations upon DGAT1 inhibition in humans have been consistent with animal studies but their development as a therapeutic target for obesity, diabetes, and hyperlipidemia have been hampered due to unwanted gastro-intestinal side effects [24,25]. The gene discussed is DGAT1; the disease is obesity due to melanocortin 4 receptor deficiency.